Europe is rebuilding how it tests depression drugs

How new depression drugs are tested has run on a one-off loop for decades: each candidate tested in its own trial, against its own placebo group, with results that don't carry into the next study. A European consortium is now building a different architecture. PEARLDIVER, a multi-arm Phase 2 platform trial for major depressive disorder (MDD), is targeted to launch in 2026 across six European countries, with new candidates plugged into a single shared blinded control group under one master protocol.

A platform trial is a shared testing infrastructure: a single master protocol, one common control arm, and several experimental treatments evaluated in parallel against the same baseline. New candidates, novel or repurposed, can enter as they become available, and the same control group supports each comparison. The format is established in oncology. The consortium describes PEARLDIVER as the first platform trial of this kind in mental health, applying the same playbook to MDD, where placebo response rates are high and effect sizes are small, so single trials often lack the statistical power to tell a real signal from noise.

Each new antidepressant candidate still goes through its own randomized comparison. The difference is that all comparisons draw on the same blinded placebo group, so the platform tests each drug against a consistent baseline rather than running parallel placebo arms that can't be combined. Detailed trial simulations are available for sample sizes of 40 to 120 per arm, and additional arms can be added as new candidates arrive. The six participating centers come from the European University Hospital Alliance.

The lead is Charité – Universitätsmedizin Berlin, with Prof. Christian Otte and Prof. Stefan Gold. Operational work sits with EATRIS, which is building the platform and recruiting industry partners for individual arms. The Wellcome Trust is funding the project with more than €13 million (about $14 million at 2025 exchange rates, or £11.7 million as stated in the Charité press release) over four years. Patient representatives, including Fanni-Laura Mäntylä with the European Patients' Forum supporting the design, helped shape the protocol.

About 30 antidepressants are approved in Germany alone, and major depressive disorder remains one of the WHO-cited leading drivers of global disease burden. Effect sizes in trials have barely moved across the past generation. High placebo response, small treatment effects, and decades of failed trials have thinned the pipeline of new candidates. The platform's premise, as the consortium has put it, is that a shared control and continuous arm addition can answer more questions with fewer total patients. The underlying design paper lays out the protocol in detail.

A platform trial changes how efficiently a negative result can be detected, and how quickly a new candidate can be slotted in. It does not change whether a drug works. Regulatory uptake across European agencies isn't guaranteed, governance across six university hospitals and multiple sponsors adds friction, and the cost of building and running a multi-arm Phase 2 platform in MDD is itself significant. The second-order effects extend past any single arm. The consortium frames the design as a de-risking step for industry sponsors: a clearer go/no-go signal before committing to a Phase 3. Regulators would see a consistent comparator across candidates. Academic groups gain a shared infrastructure rather than rebuilding one per study. Patient enrolment is targeted to start in 2026, with a Clinical Trial Application submission planned for roughly the first quarter of that year. The first year builds the platform; the next stage evaluates the first two medications. If those early arms produce clear enough signals, additional candidates can be added. If they don't, the consortium will still have learned a faster, more efficient way to find out.